| Literature DB >> 35178367 |
Jinkui Wang1, Chenghao Zhanghuang1,2, Xiaojun Tan1,3, Tao Mi1, Jiayan Liu1, Liming Jin1, Mujie Li1, Zhaoxia Zhang1, Dawei He1.
Abstract
BACKGROUND: Osteosarcoma (OSC) and Ewing's sarcoma (EWS) are children's most common primary bone tumors. The purpose of the study is to develop and validate a new nomogram to predict the cancer-specific survival (CSS) of childhood OSC and EWS.Entities:
Keywords: Ewing's sarcoma; Osteosarcoma; cancer-specific survival; children; nomogram
Mesh:
Year: 2022 PMID: 35178367 PMCID: PMC8843936 DOI: 10.3389/fpubh.2022.837506
Source DB: PubMed Journal: Front Public Health ISSN: 2296-2565
Figure 1The flowchart of including and dividing patients.
Clinicopathological characteristics of children with bone tumor.
|
|
|
|
| |
|---|---|---|---|---|
| Age (median [IQR]) | 13 (10, 15) | 13 (10, 15) | 13 (10, 15) | 0.6892 |
| Race | 0.717 | |||
| White | 1,624 (78.9%) | 955 (78.6%) | 669 (79.3%) | |
| Black | 233 (11.3%) | 143 (11.8%) | 90 (10.7%) | |
| Other | 202 (9.81%) | 117 (9.63%) | 85 (10.1%) | |
| Sex | 0.020 | |||
| Male | 1,179 (57.3%) | 722 (59.4%) | 457 (54.1%) | |
| Female | 880 (42.7%) | 493 (40.6%) | 387 (45.9%) | |
| Grade | 0.933 | |||
| I | 23 (1.12%) | 14 (1.15%) | 9 (1.07%) | |
| II | 48 (2.33%) | 27 (2.22%) | 21 (2.49%) | |
| III | 419 (20.3%) | 248 (20.4%) | 171 (20.3%) | |
| IV | 747 (36.3%) | 433 (35.6%) | 314 (37.2%) | |
| Unknown | 822 (39.9%) | 493 (40.6%) | 329 (39.0%) | |
| Stage | 0.591 | |||
| Localized | 673 (32.7%) | 398 (32.8%) | 275 (32.6%) | |
| Regional | 842 (40.9%) | 484 (39.8%) | 358 (42.4%) | |
| Distant | 531 (25.8%) | 325 (26.7%) | 206 (24.4%) | |
| Unstaged | 13 (0.63%) | 8 (0.66%) | 5 (0.59%) | |
| Year of diagnosis | 0.651 | |||
| 2004–2010 | 860 (41.8%) | 502 (41.3%) | 358 (42.4%) | |
| 2010–2018 | 1,199 (58.2%) | 713 (58.7%) | 486 (57.6%) | |
| Primary site | 0.713 | |||
| Limb | 1,576 (76.5%) | 926 (76.2%) | 650 (77.0%) | |
| Cranial | 93 (4.52%) | 55 (4.53%) | 38 (4.50%) | |
| Spine | 56 (2.72%) | 35 (2.88%) | 21 (2.49%) | |
| Thoracic | 118 (5.73%) | 76 (6.26%) | 42 (4.98%) | |
| Pelvic | 216 (10.5%) | 123 (10.1%) | 93 (11.0%) | |
| Histologic type | 0.832 | |||
| Osteogenic sarcoma | 1,385 (67.3%) | 820 (67.5%) | 565 (66.9%) | |
| Ewings sarcoma | 674 (32.7%) | 395 (32.5%) | 279 (33.1%) | |
| Laterality | 0.789 | |||
| Left | 952 (46.2%) | 563 (46.3%) | 389 (46.1%) | |
| Right | 901 (43.8%) | 535 (44.0%) | 366 (43.4%) | |
| Not a paired site | 206 (10.0%) | 117 (9.63%) | 89 (10.5%) | |
| Chemotherapy | 0.189 | |||
| No/Unknown | 81 (3.93%) | 54 (4.44%) | 27 (3.20%) | |
| Yes | 1,978 (96.1%) | 1,161 (95.6%) | 817 (96.8%) | |
| Radiation | 0.937 | |||
| No/Unknown | 1,674 (81.3%) | 989 (81.4%) | 685 (81.2%) | |
| Yes | 385 (18.7%) | 226 (18.6%) | 159 (18.8%) | |
| Surgery | 0.926 | |||
| No | 321 (15.6%) | 193 (15.9%) | 128 (15.2%) | |
| Partial resection | 230 (11.2%) | 136 (11.2%) | 94 (11.1%) | |
| Radical excision | 1,166 (56.6%) | 681 (56.0%) | 485 (57.5%) | |
| Amputation | 342 (16.6%) | 205 (16.9%) | 137 (16.2%) | |
| Tumor size (median [IQR]) | 90 (62, 125) | 90 (63, 125) | 88.5 (61.75, 125.25) | 0.7592 |
| Metastasis | 0.469 | |||
| No/Unknown | 1,585 (77.0%) | 928 (76.4%) | 657 (77.8%) | |
| Yes | 474 (23.0%) | 287 (23.6%) | 187 (22.2%) |
Univariate and multivariate analyses of CSS in bone tumor.
|
|
| |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Age | 1.06 | 1.03–1.09 | <0.0001 | 1.030 | 1.006–1.055 | 0.015 |
| Sex | ||||||
| Male | Reference | |||||
| Female | 0.87 | 0.72–1.07 | 0.19 | |||
| Year of diagnosis | ||||||
| 2004–2010 | Reference | |||||
| 2011–2018 | 0.53 | 0.43–0.64 | <0.0001 | |||
| Race | ||||||
| White | Reference | |||||
| Black | 1.13 | 0.83–1.53 | 0.45 | |||
| Other | 0.94 | 0.67–1.31 | 0.71 | |||
| Primary site | ||||||
| Limb | Reference | |||||
| Cranial | 0.45 | 0.24–0.83 | 0.01 | 0.772 | 0.425-1.401 | 0.394 |
| Spine | 1.21 | 0.67–2.19 | 0.52 | 1.760 | 1.021–3.033 | 0.042 |
| Thoracic | 1.03 | 0.67–1.59 | 0.88 | 1.232 | 0.814–1.864 | 0.324 |
| Pelvic | 2.12 | 1.58–2.85 | <0.0001 | 1.396 | 1.045–1.863 | 0.024 |
| Grade | ||||||
| I | Reference | |||||
| II | 0.48 | 0.14–1.65 | 0.25 | |||
| III | 0.85 | 0.33–2.22 | 0.75 | |||
| IV | 1.17 | 0.45–3 | 0.75 | |||
| Unknown | 0.97 | 0.38–2.5 | 0.95 | |||
| Histologic type | ||||||
| Osteogenic sarcoma | Reference | Reference | ||||
| Ewings sarcoma | 0.89 | 0.72–1.1 | 0.28 | 0.563 | 0.434–0.73 | <0.0001 |
| Laterality | ||||||
| Left | Reference | |||||
| Right | 0.91 | 0.74–1.11 | 0.35 | |||
| Not a paired site | 0.99 | 0.7–1.38 | 0.93 | |||
| Stage | ||||||
| Localized | Reference | Reference | ||||
| Regional | 2.3 | 1.74–3.03 | <0.0001 | 1.743 | 1.348–2.255 | <0.0001 |
| Distant | 5.96 | 4.48–7.93 | <0.0001 | 4.400 | 3.396–5.701 | <0.0001 |
| Unstaged | 1.27 | 0.28–5.85 | 0.75 | 1.309 | 0.319–5.377 | 0.709 |
| Surgery | ||||||
| No | Reference | Reference | ||||
| Partial resection | 0.55 | 0.37–0.8 | <0.0001 | 0.707 | 0.499–1.002 | 0.051 |
| Radical excision | 0.46 | 0.35–0.6 | <0.0001 | 0.503 | 0.382–0.663 | <0.0001 |
| Amputation | 0.87 | 0.63–1.2 | 0.40 | 0.742 | 0.545–1.01 | 0.058 |
| Radiation | ||||||
| No/Unknown | Reference | |||||
| Yes | 1.63 | 1.28–2.07 | <0.0001 | |||
| Chemotherapy | ||||||
| No/Unknown | Reference | |||||
| Yes | 2.31 | 1.21–4.4 | 0.01 | |||
| Tumor size | 1 | 1–1.01 | <0.0001 | 1.002 | 1.001–1.003 | 0.006 |
| Metastasis | ||||||
| No | Reference | |||||
| Yes | 3.58 | 2.88–4.46 | 3.58 | |||
Other: American Indian/AK Native, Asian/Pacific Islander.
Figure 2Nomogram for 3-, 5-, and 8-year CSS of children with OSC and EWS.
Figure 3Calibration curve of the nomogram. (A–C) For 3-, 5-, and 8-year CSS in the training set; (D–F) for 3-, 5-, and 8-year in the validation set.
Figure 4The ROC of 3-, 5-, and 8-year of the training (A) and validation (B) sets.
Figure 5Decision curves of the nomogram predicting CSS in the training set (A) and the validation set (B). The x-axis is the threshold probability, and the y-axis is the net benefit. The green line indicates that no patients have died, and the dark green line indicates that all patients have died. When the threshold probability is between 10 and 50%, the net benefit of the model exceeds all deaths or no deaths.
Figure 6Kaplan–Meier curves of CSS for children in the low- and high-risk groups in the training set (A) and validation set (B).
Figure 7Kaplan–Meier curves of CSS for children with different surgery in the low- (A) and high-risk (B) groups in total set.